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Haemostasis is a physiological process that 
stops blood loss at the site of injury, while 
maintaining normal blood flow in the rest of 
the circulation. 
This is accomplished in three physiological 
steps that occur in rapid sequence: (i) vaso­
constriction; (ii) formation of a platelet plug 
(primary haemostasis); and (iii) stabilisation 
of the clot through cross­linking of insoluble 
fibrin (secondary haemostasis). Apart from 
limiting blood loss, the clot allows for vessel 
and tissue repair. 
Anticoagulant mechanisms regulate the 
coagulation system to ensure formation of 
a clot that is proportional to the injury. A 
delicate balance between procoagulant and 
anticoagulant systems is critical for proper 
haemostasis and for avoiding pathological 
bleeding or thrombosis. The clot is finally 
dissolved by the fibrinolytic system, which 
also performs the function of preventing 
blood clots in healthy blood vessels (Fig. 1). 
Any disturbance to the vessel wall, vascular 
flow or balance between procoagulant and 
anticoagulant molecules in the blood (i.e. 
Virchow’s triad) may result in thrombosis.[1] 
Thrombotic disorders may be categorised 
as either arterial or venous, where the 
symptoms and pathophysiological processes 
are quite distinct. Arterial thrombosis is 
usually preceded by damage to the arterial 
wall. Symptoms include pain at the site of 
hypoxia and/or loss of function distal to 
the site of obstruction due to ischaemia/
infarction. Venous thrombosis may cause 
discomfort or pain and is often accompanied 
by oedema distal to the thrombus. Large­
vein thromboses (calf and popliteal veins) 
carry a higher risk of pulmonary embolism.
The focus of this article (part 1 of a 2­part 
CME series) is inherited thrombophilia, 
where diagnostic and pathophysiological 
aspects are discussed. Acquired thrombo­
philia is discussed in part 2 (next issue). 
Management and prevention of thrombosis 
are beyond the scope of this CME; we refer 
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Thromboembolic conditions are the leading cause of mortality, estimated to account for 1 in 4 deaths worldwide in 2010. Over time, 
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The haemostatic system comprises 6 main components, i.e. (i) platelets; (ii) vascular endothelium; (iii) coagulation proteins; (iv) natural 
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a prothrombotic or prohaemorrhagic state. In this issue of CME, the first of a 2-part series on thrombophilic disorders, the subject of 
discussion is on inherited varieties that the general practitioner is likely to encounter. This review is primarily based on venous thrombosis.
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Fig. 1. Coagulation cascade. Dotted arrows indicate actions of natural anticoagulants and fibrinolytic 
factors. (V, VIII, IX, X, XI, XIII = procoagulant factors; suffix a = activated factor; AT = antithrombin; 
TF = tissue factor; I = fibrinogen; II = thrombin; Plg = plasminogen; PL = phospholipid (on platelet 
membrane); TFPI = tissue factor pathway inhibitor; tPA = tissue plasminogen activator; PT = pro­
thrombin; APC = activated protein C; PS = protein S; TM = thrombomodulin; α2AP = α2­antiplasmin; 
PC = protein C.)
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the reader to the local guidelines for more information in this 
regard.[2] 
Inherited thrombophilia due 
to abnormalities of natural 
anticoagulants
Antithrombin deficiency
Antithrombin (AT), a serine protease, is a key regulator of the 
coagulation system. It is a natural inhibitor of active clotting factors, 
particularly thrombin and factor X (FX) and, to a lesser extent, 
FXII, FXI, FIX and FVII. Its complete absence from the body is 
incompatible with life, and the natural inhibitory activity of AT is 
accelerated by the conformational change that occurs when bound 
to heparin.[3] AT further regulates inflammation in the vascular 
endothelium, controls microvascular leakage and inhibits pro­
inflammatory cytokines. Inadequate activity levels of AT in plasma 
increase the risk of thrombotic events, both in the venous and, to a 
lesser extent, arterial circulation, and deficiencies can be inherited or 
acquired. AT is produced mainly in the liver, but also in endothelial 
cells. Congenital AT deficiency constitutes the most significant 
inherited thrombophilic condition, with an odds ratio of up to 20 
for the development of venous thrombosis in the heterozygous state, 
which is increased further in the presence of acquired risk factors, 
such as pregnancy and malignancy. More than 250 mutations in 
the AT gene have been reported. Population­wide screening of this 
condition, albeit controversial, occurs in an estimated 0.2% of the 
population.[4] Occurrence of a first thrombotic event in patients with 
congenital deficiency is related more to the type of genetic mutation, 
the presence of concomitant acquired predisposing conditions and 
the patient’s age than to AT plasma levels.
Acquired AT deficiency occurs in a variety of physiological and 
pathological conditions with similar risks of increased throm ­
bosis.[5] The mechanism of AT depletion in acquired deficiencies 
relates to reduced hepatic synthesis, increased consumption, 
abnormal leakage from the circulation, blood dilution and the effect of 
drugs.[6] Acquired causes of AT deficiency include pregnancy, ovarian 
hyperstimulation syndrome, liver failure, nephrotic syndrome, 
inflammatory bowel disease, the postsurgical period, sepsis, thermal 
injury, heparin therapy and massive venous thrombosis. Long­term 
anticoagulation therapy is often indicated after a thrombotic event, 
and in high­risk situations AT concentrates are a treatment option for 
patients with congenital AT deficiency.[4] 
Protein C and protein S deficiency
Protein C (PC) is a vitamin K­dependent natural anticoagulant 
produced mainly in the liver. PC is activated by thrombin via its 
interaction with thrombomodulin and endothelial PC receptor in 
the presence of protein S (PS) (Fig. 1). Activated PC inactivates 
membrane­bound activated coagulation FV and FVIII.[7] PC has a 
plasma half­life of 6 ­ 8 hours. Congenital PC deficiency is caused 
by >160 mutations thus far identified in the PC gene.[8] Heterozygous 
PC deficiency occurs in ~0.5% of the general population and in 3 ­ 
9% of random patients with a first venous thromboembolic event 
(VTE). The risk of thrombosis in congenital PC deficiency increases 
further in association with other risk factors, such as pregnancy.[9,10] 
Homozygous PC deficiency results in severely low PC levels and 
can cause intrauterine fetal death or present with purpura fulminans 
and disseminated intravascular coagulation in the newborn, which 
may necessitate long­term anticoagulation and replacement therapy 
with fresh frozen plasma or PC concen trates.[11,12] Congenital 
PC deficiency can be either quantitative (type I) or qualitative (type II), 
and laboratory assays are available for distinguishing between 
these subtypes. Acquired PC deficiency is more common than 
inherited genetic abnormalities and relates to vitamin K deficiency, 
which occurs with oral anticoagulant therapy and liver synthetic 
dysfunction. Acquired causes must be excluded prior to considering 
a congenital cause of low PC levels.[11,12] 
PS is also a vitamin K­dependent factor produced in the liver 
and endothelial cells, which enhances the anticoagulant activity of 
PC, and its deficiency is associated with an increased thrombotic 
risk. PS in the plasma has a half­life of 42 hours and exists in two 
forms, i.e. PS bound to complement 4b­binding protein (60%), 
which is the inactive PS component, and free PS (40%), which is the 
physiologically active component. These two components comprise 
the total PS in the plasma. Congenital PS deficiency is estimated to 
be present in <0.5% of the general white population and 2 ­ 12% of 
selected groups with venous thromboembolic disease, and consists 
of type I (reduced total and free antigen), type II (normal total and 
free antigen, but reduced activity) and type III (normal total antigen, 
but reduced free antigen resulting in reduced activity) deficiencies. 
Type I and type III account for 95% of cases of congenital PS 
deficiency.[7,8] Acquired causes of PS deficiency are encountered 
more frequently and relate to vitamin K deficiency due to treatment 
with vitamin K antagonists (e.g. warfarin), liver disease, severe and 
chronic inflammation, autoimmune syndromes, nephrotic syndrome, 
pregnancy and viral infections, such as HIV. 
Patients with congenital PC or PS deficiency have a 2 ­ 11­fold 
increased risk of a VTE (deep­vein thrombosis (DVT) with or 
without pulmonary embolism (PE)) in comparison with unaffected 
individuals, although the final occurrence of a VTE depends 
on multiple underlying genetic and acquired factors. Patients 
with PC/PS deficiency may manifest with cerebral, visceral or 
axillary vein thrombosis, but these thromboses are less common. 
PC/PS­deficient patients are also at risk of warfarin­induced skin 
necrosis.[8] Some studies have suggested an association between PC/PS 
deficiencies and arterial thromboses, such as ischaemic stroke, but 
this is not conclusive.[12] The development of thrombosis in PC/
PS­deficient patients may occur in association with other congenital 
conditions, such as the FV Leiden mutation, or provoked by acquired 
conditions such as pregnancy.[7] The estimated annual incidence 
of a VTE in PC­deficient (0.7%) and PS­deficient (0.8%) patients 
is higher than in those with the FV Leiden mutation. Provoked 
venous thromboembolic episodes in patients with PC/PS deficiencies 
are labelled as low­risk events and are treated with short­term 
anticoagulation for 3 ­ 6 months. Heparin should be administered 
for at least 1 day prior to the introduction of warfarin to prevent skin 
necrosis. Patients with idiopathic unprovoked events are considered 
at high risk for VTE recurrence and may benefit from lifelong 
anticoagulation. Ongoing thromboprophylaxis is not recommended 
in asymptomatic individuals with PC/PS deficiencies.[13] 
Activated protein C resistance 
A single nucleotide substitution in the FV gene, known as the FV Leiden 
mutation, is a common genetic abnormality that predisposes carriers 
to a VTE.[14] This mutation renders FV relatively resistant to cleavage 
by activated PC, thereby promoting thrombin generation. Additional 
rare point mutations have been described, i.e. FV Hong Kong and 
FV Cambridge, which are also associated with activated PC (APC) 
resistance and increased risk of venous thromboembolism. The risk 
of a VTE is increased 2 ­ 7­fold in heterozygotes and 40 ­ 80­fold 
in individuals homozygous for FV Leiden.[15] FV Leiden is common 
in the white population, with a prevalence of 3 ­ 7%. However, the 
mutation has not been associated with thrombosis among black 
population affinity groups.[16] 
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FV Leiden testing is performed by functional testing for APC 
resistance or by DNA testing for the Arg506Gln mutation. The 
optimal management of carriers and their relatives should be guided 
by familial penetrance, characteristics of the first VTE (e.g. pro­
voked/unprovoked, age) and laboratory biomarkers.[17]
Inherited thrombophilia due to 
increased thrombotic potential
Prothrombin mutation
The prothrombin polymorphism G20210A is a common genetic 
abnormality that predisposes carriers to a VTE. The polymorphism 
is characterised by increased prothrombin activity, which is the 
precursor of thrombin. Similar to the FV Leiden mutation, the 
prothrombin gene mutation is also prevalent in white populations 
(0.7 ­ 4.0%).[18] Several studies have shown that this polymorphism 
is a low­to­moderate risk factor for a VTE.[19] The risk of a VTE 
is increased 2 ­ 3­fold in heterozygotes and up to 19­fold in homo­
zygotes. The polymorphism is an important risk factor in conjunc­
tion with the FV Leiden mutation or acquired thrombotic risk 
factors (e.g. oral contraceptive therapy, pregnancy, immobilisation, 
surgery).[20]
Prothrombin gene testing is performed by DNA testing for 
G20210A. The optimal management of carriers and their relatives 
should be guided by familial penetrance, characteristics of the first 
VTE (e.g. provoked/unprovoked, age) and the presence of acquired 
or additional inherited thrombotic risk factors.[20]
Increased coagulation factor levels
Coagulation factors play a central role in the initiation and 
amplification of secondary clot formation. Increased coagulation 
factor levels, i.e. FII, FVII, FVIII, FIX, FX, FXI, ﬁbrinogen and 
Von Willebrand factor, are associated with an increased VTE risk.[13,21] 
In contrast, elevated levels of FV, FXII and FXIII have not been 
associated with a VTE. FVIII has been shown to be the strongest 
risk factor.[21] In the coagulation cascade, activated FVIII, which 
is the cofactor of FIX, potentiates the generation of thrombin. 
The molecular mechanism underlying elevated FVIII levels is, 
however, not clear.[22] It is likely that elevated FVIII levels alone 
are insufficient to cause a VTE, but that the risk is increased in the 
presence of other causal factors.
Testing for FVIII is often included as part of a thrombotic screen in 
patients with venous thromboembolic disease. As FVIII is an acute­
phase reactant, it is important to perform testing after the thrombotic 
acute­phase response. Increased FVIII levels have been detected in 
~25% of patients with VTEs. Owing to the increased risk of recurrent 
VTEs, high FVIII levels can be used to risk stratify patients for 
extended thromboprophylaxis.[23]
Increased plasminogen activator inhibitor-1 levels
The primary mediator of fibrinolysis is tissue plasminogen activator 
(tPA). Plasminogen activator inhibitor­1 (PAI­1) is the primary 
inhibitor of tPA. It is released from endothelial cells, platelets, 
monocytes and hepatocytes in response to inflammatory stimuli or 
upregulation of thrombin. Family studies have reported a 4G/5G 
poly morphism, located in the promoter region of the PAI­1 gene, 
to be associated with elevated PAI­1 levels.[24] Increased levels of 
PAI­1 with impaired fibrinolysis predispose to a VTE. However, 
studies of the role of elevated levels of PAI­1 in patients with 
venous thromboemblic disease have shown conflicting results.[25] 
This suggests that elevated PAI­1 is insufficient to cause a VTE, but 
that the risk is marginally increased in the presence of other causal 
factors, including inflammation or other prothrombotic conditions.[26] 
Further studies are indicated before treatment recommendations can 
be made. Genetic testing for the 4G/5G polymorphism and PAI­1 
levels may be used for diagnostic purposes, but are not routinely 
available.
Dysfibrinogenaemia
Dysfibrinogenaemia encompasses a group of disorders that may 
be inherited or acquired and is characterised by normal or reduced 
fibrinogen antigen levels, but disproportionately low ﬁbrinogen 
activity levels (qualitative ﬁbrinogen defect).[27] Acquired conditions 
are most commonly encountered in the context of liver dysfunction. 
The inherited varieties are rare. Patients may present with bleeding, 
a VTE (often at a young age) or poor obstetric history. However, 
most individuals are asymptomatic and are usually identified by the 
prolongation of screening coagulation tests. It has been proposed 
that abnormal fibrinogen predisposes to a VTE, either as a result 
of defective binding with thrombin, and/or decreased tPA­mediated 
fibrinolysis by plasmin. Dysﬁbrinogenaemia is characterised by 
prolongation of the prothrombin time, activated partial thrombo plastin 
time (APTT) and thrombin time. The diagnosis of dysﬁbrinogenaemia 
is based on the assessment of functional and antigenic ﬁbrinogen. 
Specialised testing, such as genetic analysis, is also required.[28] 
Recommendations for patient management are derived from 
expert consensus guidelines.[29] Management should be considered 
in conjunction with a personal and family history of bleeding or 
thrombosis. Specific management in the setting of surgery and 
pregnancy requires a multidisciplinary team. Close follow­up of 
asymptomatic patients is advised owing to the risk of complications 
during the natural course of the disease. 
Miscellaneous inherited 
thrombophilias
Protein Z deficiency 
Protein Z (PZ) is a vitamin K­dependent factor with homology 
to other vitamin K­dependent factors such as prothrombin, PC 
and PS, but it lacks enzymatic activity. Instead, PZ acts as a 
cofactor for the PZ­dependent protease inhibitor (ZPI), which 
inhibits FXa. PZ deficiency is postulated to be associated with a 
procoagulant state, playing a pathogenic role in arterial and venous 
thromboembolic diseases.[30] An association between altered plasma 
PZ concentrations and adverse pregnancy outcomes, including 
recurrent miscarriage and pre­eclampsia, has been demonstrated. 
The mechanism of PZ deficiency in pregnant patients, with resultant 
obstetric complications, may relate to anti­PZ autoantibodies.[31] The 
roles of PZ plasma activity and PZ gene polymorphisms, however, 
remain poorly defined, with conflicting results of studies, where 
some report low PZ levels in association with an increased risk of 
venous thrombosis and pregnancy complications, whereas others did 
not observe this association.[32] Routine measurement of PZ levels does 
not currently form part of the laboratory assessment of thrombosis risk.
Tissue factor pathway inhibitor 
Tissue factor pathway inhibitor (TFPI), produced in endothelial cells, 
regulates the tissue factor (TF) pathway. The process of coagulation 
commences with TF, which binds and activates FVII. This results in 
the production of thrombin (FIIa) on the surface of a TF­bearing cell. 
This initial generation of thrombin is very short lived, as TF:FVIIa is 
very rapidly inactivated by TFPI. Lower TFPI levels are associated 
with increased thrombin generation. Low plasma levels of TFPI have 
been observed in patients with venous thromboembolic disease and 
stroke.[33­35] However, a signiﬁcant association between low TFPI levels 
and an increased risk of a VTE has not been consistently demonstrated.
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Testing for TFPI is not routinely available. To date, there is no strong 
evidence to suggest that TFPI deficiency should be considered a 
clinically significant prothrombotic condition. Further studies are 
indicated before treatment recommendations can be made.
Thrombomodulin deficiency
Thrombomodulin is a surface receptor expressed by intact healthy 
endothelial cells and binds thrombin that has diffused away from the 
site of endothelial damage. In addition to blocking the procoagulant 
function of thrombin, the binding of thrombin to thrombomodulin 
brings it into close proximity of PC, leading to inactivation of FV and 
FVIII. Consequently, mutations of the thrombomodulin gene (THBD) 
have been considered a risk factor for a VTE. These mutations are, 
however, rare and evidence from clinical trials suggests that these are 
not significant risk factors for venous thromboembolic disease.[36,37] 
These polymorphisms are predominantly seen in African­American 
populations, in contrast to FV Leiden and prothrombin G20210A 
gene mutations.[38]
Testing for mutations of the thrombomodulin gene is not 
routinely available. There is to date no strong evidence to suggest 
that these mutations should be considered a clinically significant 
prothrombotic condition. Further studies are indicated before 
treatment recommendations can be made. 
Hyperhomocysteinaemia
Homocysteine is an intermediate product of methionine meta­
bolism. Levels of homocysteine are regulated by the enzyme, 
methylenetetrahydrofolate reductase (MTHFR). Genetic mutations 
of this enzyme result in hyperhomocysteinaemia and an increased 
risk of cardiovascular disease. In addition, homocysteine levels are 
influenced by ethnic and regional differences, reduced folic acid, 
vitamin B12 and vitamin B6 levels, lifestyle, medical conditions 
and drugs. Homocysteine levels >15 μmol/L are defined as 
hyperhomocysteinaemia. Mild hyperhomocysteinaemia is a common 
laboratory finding. While the role of homocysteine in arterial disease 
has been well researched, its role in venous thromboembolic disease 
is controversial. It is not clear from the available evidence whether 
hyperhomocysteinaemia is the cause or consequence of a VTE. A 
meta­analysis concluded that hyperhomocysteinaemia is a weak risk 
factor for a VTE.[39]
Currently, there is insufficient evidence to support the testing of 
fasting homocysteine levels in patients with venous thromboembolic 
disease.[40] Furthermore, there is insufficient evidence for vitamin 
supplementation in hyperhomocysteinaemia, in particular with 
folic acid and vitamin B12.
[41] Vitamin supplementation, however, 
is advised in patients with folate or vitamin B12 deﬁciency. Patients 
should be educated regarding the uncertain role of this treatment in 
the prevention of recurrence of a VTE.
Laboratory testing
FV Leiden, prothrombin gene mutations and antiphospholipid 
antibodies, which will be discussed in part 2 of this CME series, 
constitute the most prevalent thrombophilias. Deficiencies of the 
natural anticoagulants (PC, PS and AT) and elevated homocysteine 
levels have a lower yield and should generally be limited to 
patients with high­risk and unique presentations. Patients with 
unprovoked splanchnic vein thrombosis should also be assessed 
for myeloproliferative neoplasms and paroxysmal nocturnal 
haemoglobinuria. Selection criteria for appropriate VTE testing are 
listed in Table 1.
It should be noted that first­degree relatives of patients with a 
prior VTE are at elevated risk, even if thrombophilia testing results 
are negative in the index patient. Thrombophilia testing need not be 
done in patients with a clear provoking event, such as recent major 
orthopaedic surgery in the absence of other factors suspicious for 
thrombophilia or in cases of underlying malignancy, as results are 
unlikely to alter the treatment plan.[42]
Timing of sample collection
Samples for FV Leiden and prothrombin gene mutation, as well 
as serological antiphospholipid antibodies such as anticardiolipin 
antibodies, can be collected in the acute phase of thrombosis, as 
the results are not affected by acute thrombosis or anticoagulants. 
Functional lupus anticoagulant testing in the coagulation laboratory, 
and testing for PC, PS and AT deficiencies, should be delayed until 
completion of anticoagulation therapy. However, in patients who 
might require lifelong anticoagulation, samples should be collected 
in the acute phase prior to initiation of therapy.
Conclusions
Venous thromboembolic disease is an important cause of morbidity 
and mortality. In southern Africa, the HIV epidemic has unexpectedly 
caused a concurrent VTE epidemic, which has not been recognised. 
Clinicians in southern Africa need to become more cognisant of this 
devastating disease. It is hoped that this review helps to address 
the problem. Patients who have had a VTE can be assessed and the 
majority of inherited and acquired disorders can be diagnosed. This 
will assist the clinician in deciding on the duration of anticoagulation, 
as well as help determine whether family studies are indicated to 
prevent a possible devastating thrombosis.
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